Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Saffron (Crocus sativus) has been investigated for its potential role in supporting or treating Alzheimer's Disease (AD), and there is a growing body of scientific evidence supporting its use. Several clinical studies, including randomized controlled trials, have evaluated saffron extract in patients with mild to moderate AD. Notably, a 2010 double-blind study published in the Journal of Clinical Pharmacy and Therapeutics found that saffron (30 mg/day) was as effective as donepezil, a standard AD medication, in improving cognitive function over a 22-week period, with fewer side effects. Another randomized, placebo-controlled trial published in Psychopharmacology (2010) showed significant cognitive improvements in the saffron group compared to placebo. The proposed mechanisms for saffron’s effects include its antioxidant, anti-inflammatory, and anti-amyloid properties, potentially inhibiting the aggregation of beta-amyloid plaques—a hallmark of Alzheimer's pathology. Saffron’s active compounds, such as crocin and safranal, are thought to play key roles in these neuroprotective actions. Although these results are promising, the overall number of large-scale, high-quality studies remains limited, and further research is needed to confirm saffron’s efficacy and safety relative to established treatments. Therefore, saffron is rated as having moderate evidence (3/5) for supporting cognitive function in AD, with its use being scientifically rather than purely traditionally justified.

More about saffron
More about Alzheimer's Disease

Other ingredients used for Alzheimer's Disease

Other health conditions supported by saffron

Products containing saffron